OP07: Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResourceECCO'24 Stockholm
2024
OP08: Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibilityECCO'24 Stockholm
2024
OP09: Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella studyECCO'24 Stockholm
2024
OP10: Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extensionECCO'24 Stockholm
2024
OP11: Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD BioresourceECCO'24 Stockholm
2024
OP12: Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trialECCO'24 Stockholm
2024
OP13: Anti-integrin ⍺vβ6 autoantibodies are increased in PSC-IBD and correlate with liver disease severityECCO'24 Stockholm
2024
OP14: Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative ColitisECCO'24 Stockholm
2024
OP15: High-definition white light endoscopy with segmental re-inspection is non-inferior compared to dye-based chromoendoscopy in Inflammatory Bowel Disease: the randomized controlled HELIOS trialECCO'24 Stockholm
2024
OP17: IBD ulcers are characterized by bioactive interleukin-1 and transcriptomic hallmarks of stromal cell state reprogrammingECCO'24 Stockholm
2024
OP18: Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn’s Disease: results from the global ADMIRE-CD II phase 3 studyECCO'24 Stockholm
2024
OP20: Postoperative endoscopic recurrence after resection of Crohn’s terminal ileitis with Kono-S or side-to-side functional end anastomosis: results of a Multicenter Prospective Randomized TrialECCO'24 Stockholm
2024
OP22: Topical Sphingosine-1-Phosphate (S1P) Receptor 1 Modulation Regulates Gut Angiogenesis in Inflammatory Bowel DiseasesECCO'24 Stockholm
2024
OP23: Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative ColitisECCO'24 Stockholm
2024